

AstraZeneca PLC 2015 Annual General Meeting



AstraZeneca PLC 2015 Annual General Meeting

Welcome to our Annual General Meeting
24 April 2015



AstraZeneca PLC 2015 Annual General Meeting

Leif Johansson
Chairman



AstraZeneca PLC 2015 Annual General Meeting

Marcus Wallenberg
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Geneviève Berger
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Shriti Vadera
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Graham Chipchase
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

John Varley
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Pascal Soriot
Chief Executive Officer



AstraZeneca PLC 2015 Annual General Meeting

Marc Dunoyer
Chief Financial Officer



AstraZeneca PLC 2015 Annual General Meeting

Rudy Markham
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Bruce Burlington
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Ann Cairns
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Jean-Philippe Courtois
Non-Executive Director



AstraZeneca PLC 2015 Annual General Meeting

Leif Johansson
Chairman



AstraZeneca PLC 2015 Annual General Meeting

Nancy Rothwell

Non-Executive Director



John Varley

Non-Executive Director




AstraZeneca PLC 2015 Annual General Meeting



AstraZeneca PLC 2015 Annual General Meeting

Cori Bargmann
Proposed Non-Executive Director





ROBECOSAM
Sustainability Award
Bronze Class 2015



AstraZeneca PLC 2015 Annual General Meeting




AstraZeneca PLC 2015 Annual General Meeting

Pascal Soriot
Chief Executive Officer



We push the boundaries of science to deliver life-changing medicines



Three strategic priorities

1

**Achieve
scientific
leadership**

2


**Return
to growth**

3

**Be a great
place to work**



Achieve scientific leadership: focus on R&D in three main therapy areas and across key platforms



Achieve scientific leadership: 12 approvals in 2014

Industry-leading number of US NDA/BLA approvals in 2014



Additional approvals



Duaklir Genuair



On track to deliver 7-8 potential new molecular entity submissions in 2015-2016

CAZ AVI (CEPH/BLI)
serious infections

cediranib (VEGFR)
ovarian cancer (EU)

selumetinib (MEK)
uveal melanoma

AZD9291 (EGFR)
2L NSCLC

brodalumab* (IL-17R)
psoriasis

PT003 (LAMA/LABA)
COPD

2015

savolitinib (AZD6094, MET)
papillary renal cell carcinoma

tremelimumab (CTLA-4)
mesothelioma

MEDI4736 (PD-L1)
3L NSCLC

roxadustat (HIF-PHI)
CKD / ESRD (China)

benralizumab (IL-5R)
severe asthma

2016

* Partner Amgen to manage regulatory submission



Q1 2015 new molecular entity† pipeline

Phase 1

30 New Molecular Entities

Small molecule	Large molecule
A7N3759 EGFR NSCLC	MFN0562# ROX40 solid tumours
AZD5312# androgen receptor/prostate	MEDI0639# DLL 4 solid tumours
A7D673R ATR CLL, H&N	MFN0680 PD-1 solid tumours
AZD8186 PI3K# solid tumours	MEDI3617# AKC-2 solid tumours
AZD8835 PI3K# solid tumours	MEDI565# CEA BITE GI tumours
AZD9159# STAT3 haems & solids	MEDI0639# OX40 P solid tumours
AZD9496 SERD ER+ breast	MEDI6469# mOX40 solid tumours
AZD1419# TLR9 asthma	MEDI4920 CD40L-Tri3 Primary Sjögrens
AZD7534 Inhaled SGRM asthma, COPD	MEDI5872# BTRP1 SLE
AZD7986 DRP1 COPD	MEDI7863 IL-13 asthma
AZD8999 MABA asthma, COPD	MEDI0392 GLP-1/gliuzagon diabetes, obesity
AZD8108 NMDA suicidal ideation	MEDI6012 LCAT ACS
	MEDI0111 Rh-Factor II trauma, bleeding
	MEDI1814 amyloid Alzheimer's
	MEDI3902 Psl/PcrV pseudomonas
	MEDI550 pandemic influenza virus vaccine
	MEDI7510 sF+GLA-SERSV prevention
	MEDI8852 influenza A treatment

Phase 2

29 New Molecular Entities

Small molecule	Large molecule
A7N1775# Wee-1 ovarian	MFN1551# CD19 CLL, DLBCL
AZD2014 mTOR 1/2 solid tumours	MEDI573# ICP metastatic breast cancer
A7N4547 FGFR solid tumours	androlumab# IFN#R SLE
AZD5363# AKT breast cancer	AZD9412# Inhaled β2 agonist asthma, COPD
AZD6094# MET pRCC	mavrilimumab# GM-CSFR rheumatoid arthritis
abediterol (AZD0540) LADA asthma, COPD	MEDI2070# IL-23 Crohns
AZD7624 Inhaled p38 inhibitor COPD	MEDI561# CD19 neuromyelitis optica#
PT010 LABA/LAMA/ICS COPD	MEDI7483# αβ7 Crohns, ulcerative colitis
RDEA3170 SURI hyperuricemia, gout	MEDI9229# TSLP asthma
AZD4901 PCOS	sifalimumab# IFN# SLE
tenapanor# NHE3 ESRD-P/CKD	MEDI4893 staph alpha toxin SSI
AZD3241 MPO Multiple System Atrophy	MEDI8897# RSV passive prophylaxis
AZD3299# β-secretase Alzheimer's	
AZD5213 H2K1.1 ourettes, neuropathic pain	
ATM AVI# BL/BLI SBI	
AZD5847 oxazolindione TB	
CXL# BLI/cephalosporin MRSA	

Phase 3

12 New Molecular Entities

Small molecule	Large molecule
A7D9291 EGFRm T790M NSCLC >2L	MFN1473# ATI ANTI-CTLA-4 PD-L1 NSCLC 3L
cediranib VEGF R2R ovarian	moxetumumab# CD20 HCL
selumetinib# SUNIT MEK uveal melanoma	tremelimumab# CTLA-4 mesothelioma
PT003 LABA/LAMA COPD	benralizumab# IL-5R3 severe asthma
roxadustat# HIF1H anaemia CKD/ESRD	brodalumab# IL-17R psoriasis
CAZ AVI# RECLAIM BLI/cephalosporin SSI	tralokinumab IL-13 severe asthma

Applications Under Review

1 New Molecular Entities

Small molecule	Large molecule
lesinurad SURI gout	

Terminations in Q1 2015

AZD2115 (COPD) in P2, brodalumab (asthma) in P2, MEDI-559 (RSV prophylaxis) in P1

Divestitures in Q1 2015

AZD0914 (infection) in P2

† Includes significant fixed dose combination projects, and parallel indications that are in a separate therapeutic area (See LCM chart for other parallel indications and oncology combination projects)

Project subject to milestones/royalties

‡ Registrational P2/3 study

§ Neuromyelitis optica now lead indication (Multiple sclerosis P1 study continuing)






Oncology
 RIA
 CVMD
 Neuroscience
 Infection



Achieve scientific leadership: enhanced collaboration a key driver





Return to growth: platforms delivered 15% growth and 53% of revenue in 2014

	2014 (\$m)	Growth (%)
 Brilinta/Brilique	476	70
 Diabetes	1,870	139
 Respiratory	5,063	10
 Emerging Markets	5,827	12
 Japan	2,227	(3)*

Product sales at actual exchange rates. Growth rates at constant exchange rates (CER). *Including impact from mandated price cuts



Great place to work





Q1 2015: Growth platforms deliver

	Q1 2015 \$m	Growth %
Total Revenue	6,057	1
Growth Platforms	3,404	13
<i>Brilinta/Brilique</i>	131	45
Diabetes	488	47
Respiratory	1,243	7
Emerging Markets	1,533	18
Japan	455	(2)
Core EPS	\$1.08	(3)



Total revenue and product sales at actual exchange rates. Growth rates at constant exchange rates (CER)




Oncology – our sixth growth platform



Immuno-oncology



What science can do: AZD9291



Deb's story

“Cancer treatment is being personalised and I am a big, happy beneficiary of this targeted therapy that I am on. I mean it just has extended my life and extended my quality of life.”

Deb is a non-smoker with EGFR mutation stage 4 lung cancer who has been on a clinical trial with AZD9291 for over a year



Total Shareholder Return (1 Jan 2013 to 31 Dec 2014)

Rank	Share	TSR
1	AstraZeneca PLC	72%
2	Vodafone Group PLC	63%
3	GlaxoSmithKline PLC	29%
4	Unilever PLC	28%
5	British American Tobacco PLC	27%
6	BP PLC	18%
7	Royal Dutch Shell PLC (B-shares)	14%
8	Barclays PLC	13%
9	Royal Dutch Shell PLC (A-shares)	13%
10	Diageo PLC	11%

Source: Datastream



AstraZeneca PLC 2015 Annual General Meeting



Resolutions

1. To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014
2. To confirm dividends
3. To reappoint KPMG LLP, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
 - a) Leif Johansson
 - b) Pascal Soriot
 - c) Marc Dunoyer
 - d) Cori Bargmann
 - e) Geneviève Berger
 - f) Bruce Burlington
 - g) Ann Cairns
 - h) Graham Chipchase
 - i) Jean-Philippe Courtois
 - j) Rudy Markham
 - k) Shriti Vadera
 - l) Marcus Wallenberg
6. To approve the Annual Report on Remuneration for the year ended 31 December 2014
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To authorise the Directors to disapply pre-emption rights
10. To authorise the Company to purchase its own shares
11. To reduce the notice period for general meetings
12. To approve the adoption of new Articles of Association



AstraZeneca PLC 2015 Annual General Meeting



Resolutions

1. To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014
2. To confirm dividends
3. To reappoint KPMG LLP, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
 - a) Leif Johansson
 - b) Pascal Soriot
 - c) Marc Dunoyer
 - d) Cori Bargmann
 - e) Geneviève Berger
 - f) Bruce Burlington
 - g) Ann Cairns
 - h) Graham Chipchase
 - i) Jean-Philippe Courtois
 - j) Rudy Markham
 - k) Shriti Vadera
 - l) Marcus Wallenberg
6. To approve the Annual Report on Remuneration for the year ended 31 December 2014
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To authorise the Directors to disapply pre-emption rights
10. To authorise the Company to purchase its own shares
11. To reduce the notice period for general meetings
12. To approve the adoption of new Articles of Association



**Please place your completed Polling Card in one of the boxes
as you leave the meeting room**

We expect to announce the results of the poll later today

**The results of the poll will also be published on the Investors
section of our website: www.astrazeneca.com**



AstraZeneca PLC 2015 Annual General Meeting

Thank you for attending and have a safe journey home

